A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Selumetinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Jun 2019 Status changed from active, no longer recruiting to completed.
- 11 Feb 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated